Narodowy Instytut Kardiologii Stefana Kardynala Wyszynskiego Panstwowy Instytut Badawczy
- Address
- lock Available on a paid plan
Cardiovascular Diseases
At the Narodowy Instytut Kardiologii Stefana Kardynala Wyszynskiego, the epidemiology department advances research on cardiovascular diseases by evaluating new therapeutic approaches and assessing their impact on clinical outcomes.
- Heart failure with preserved or reduced ejection fraction
- Hypertrophic cardiomyopathy and atrial fibrillation
- Coronary artery disease and atherosclerotic risk
- Hypertension, including resistant forms
- Arrhythmogenic and dilated cardiomyopathies
- Acute myocardial infarction and post‑event risk reduction
The initiative leverages extensive patient registries to uncover risk patterns and fosters multicenter collaborations throughout Europe.
Nutritional and Metabolic Diseases
Research at the institute focuses on nutritional and metabolic diseases, seeking to improve prevention strategies and evaluate therapies that address obesity, diabetes, and related metabolic disorders.
- Obesity and overweight in individuals with cardiovascular risk
- Prediabetes management in patients with coronary artery disease
- Type 2 diabetes treatment with emerging agents
- Hyperlipidemia and lipoprotein(a) lowering interventions
- Uric acid metabolism and its cardiovascular implications
By integrating metabolic profiling, the program aims to identify early biomarkers and support lifestyle‑focused interventions alongside pharmacologic options.
Respiratory Tract Diseases
The epidemiology unit also investigates respiratory tract diseases, emphasizing the interplay between breathing disorders and heart health while testing novel diagnostic and therapeutic measures.
- Obstructive sleep apnea in overweight adults
- Pulmonary hypertension secondary to heart failure with preserved ejection fraction
- Impact of chronic respiratory conditions on cardiovascular outcomes
Collaborative efforts with pulmonology specialists enable comprehensive assessments and the development of integrated care pathways for affected patients.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 5 of 6 therapeutic areas and 15 of 62 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Top 40 of 56 compounds, ranked by number of trials.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 16 by active trials.
lock +15 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
lock +10 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 1 624 other sites in Poland
Therapeutic Area Benchmark — Poland
Select a therapeutic area to compare against other sites in Poland.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Poland
Market Share
Country: Poland
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Narodowy Instytut Kardiologii Stefana Kardynala Wyszynskiego Panstwowy Instytut Badawczy
lock Showing 1 of 53 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Long-term Safety Extension Study of Mavacamten (MYK-461) in Adults with Hypertrophic Cardiomyopathy Who Have Completed the MAVERICKHCM (MYK-461-006) or EXPLORER-HCM (MYK-461-005) Trials (MAVA-LTE) | Myokardia Inc. | Phase III | Not Recruiting | Sep 2019 | Jan 2026 |
IMP list
lock Showing 1 of 62 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Acetylsalicylic Acid | 3 | Unknown | 2023-11-21 | 2023-11-21 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.